Effect of Anti-Thyroperoxidase on Thyroid Gland and Breast Tissue: A Comprehensive Review

Sabitha Kandi^1, , Venkata Bharatkumar Pinnelli², Pragna Rao³ and K V Ramana⁴

¹Department of Bio-chemistry, Chalmeda Anandarao Institute of Medical Sciences, Karimnagar, India

²Department of Bio-chemistry, Vaidehi Institute of Medical Sciences, and Research Centre, Bangalore, India

³Department of Bio-chemistry, Kasturba Medical College, Manipal Universiy, Manipal, India

⁴Department of Microbiology, Prathima Institute of Medical Sciences, Karimnagar, India

Cite this paper:
Sabitha Kandi, Venkata Bharatkumar Pinnelli, Pragna Rao and K V Ramana. Effect of Anti-Thyroperoxidase on Thyroid Gland and Breast Tissue: A Comprehensive Review. American Journal of Medicine Studies. 2014; 2(2):34-37. doi: 10.12691/ajms-2-2-2

Abstract

Relationship between thyroid disease and breast tissue has long been debated as both the tissues have same embryological origin. Recent studies have implicated the possible role of thyroid dysfunction in the development and progression of breast related disorders. In view of increased prevalence of hypo and hyper thyroidism globally, there is a possibility of hormonal imbalance which may contribute to the initiation of tumor growth. Current literature has confirmed the role of sodium-iodide symporter (NIS) gene expression in breast cancers. Elevated anti-thyroperoxidase enzyme has been associated with increased risk of breast cancer. Activity of thyroid gland in post menopausal women, role of iodide levels and its relation to breast tissue and development of breast cancer needs extensive evaluation. In this comprehensive review we describe the role of NIS in thyroid gland functioning, thyroid hormone signaling mechanism.

Keywords:
thyroid peroxidase (TPO) sodium-iodide symporter (NIS) thyroid disease breast disease

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Harry Jameson, Anthony P. Weetman chapter 320: ‘ DISORDERS OF THYROID GLAND’. Harrison’s principles of Internal medicine: 16th edition, Mc Greaw Hill medical publishing division, Newyork, vol. II: pg: 2104-2127.
[2]	The Lancet, “Breast cancer in developing countries”, The Lancet, 374997010; 1567-2131.
[3]	Tfayali A, Temroz S, Marod RA, Shamseddine A (2010) Breast cancer in low and middle income countries; an emerging and challenging epidemic. Journal of Oncology 2010: 1-5.
[4]	Kim JJ, Champan – DavisE (2010) Role of Progesterone in endometrial cancer. Semin Rerod Med 28: 81-90.
[5]	Lewis – Wambi JS, Jardon VC (2009) Estrogen region of apoptosis: how can one hormone stimulate and inhibit? Breast cancer Res 11: 2006.
[6]	Mazumdar A, Wang RA, mishra SK, Adam L, Bagheri – Yarmand R, et.al., (2001) Transcriptional repression of estrogen receptor by metasis associated protein I corepressor. Nat cell boil 3(1): 30-7.
[7]	Mishra SK, Yang Z, Manzumdar A, Talukder AH, Larose L, et.al., (2004) Metastatic tumor antigen I short form (MTAIs)associates with casein kinase I gamma 2, an estrogen responsive kinase. Oncogene 23(25): 4422-9.
[8]	Tomer Y, Huber A: The etiology of autoimmune thyroid disease: a story of genes and environment: J Autoimmun, 2009, May – Jun; 32 (3-4): 231-9.
[9]	Giustanni E, Pinchera A, Fierabracci P, Roncella M, Fustanio L, Marnmolic, et. al.,: Thyroid autoimmunity in patients with malignant and benign breast diseases before surgery: Nat Clin Pract Endocrinol Metab, 2006 Dec; 2(12): 660-1.
[10]	Silva JM, Dominguez G, Gonzalez – Sanccho JM,Gracia JM, Silva J, et.al., (2002) Expression of thyroid hormone receptor / erbA genes is altered in human breast cancer. Oncogene 21: 4307-4316.
[11]	Martrinez MB, Ruan M, LA Fizpatrick LA (2000) Altered response to thyroid hormones by prostate and breast cancer cells. Cancer chemother pharmacol 2000:45; 93-102.
[12]	Mangelsdrof D, Thummel C, Beato M, Herrlich P, Schutz G, et.al., (1995) The nuclear receptor super family: the second decade. Cell 83:835-839.
[13]	Pranati sar, Rosalima Peter, Bandita Rath, Alok Das Mohapatra, Sandip K, Mishra (2011). 3,3’5’ triiodo thyronine induces apoptosis in human breast cancer MCF-7 cells, Repressing SMP30 expression through negative thyroid response elements plos one 6(6):e20861.
[14]	Conde I, Paniagua R,Zamora J, Blanquez MJ, Fraile B, et.al., (2006) Influence of thyroid hormone receptors on breast cancer cell proliferation. Annals of Oncology 17:60-64.
[15]	Cestari SH, Figueiredo NB, Conde SJ, Clara S, Katayama MLH et.al.,(2009) Influence of estradiol and triiodothyronine on breast cancer celllines proliferation and expression of estrogen and thyroid hormone receptors. Arq Bras Endocrinol Metab 53(7): 859-64.
[16]	Guigon CJ, Kim DW, Willingham MC, Cheng S-Y (2011) Mutation of the thyroid hormone receptor - β in mice predisposes to the development of mammary tumors. Oncogene 1-10.
[17]	Bogardus GM, Finley JW: Breast cancer and thyroid disease. Surgery 1961, 49; 461-468.
[18]	Adamopoulos DA, Vassilarus S, Kapolla N, Papadiamantis J, Georgiakodis F, Michalkis A: Thyroid disease in patients with benign and malignant mastopathy. Cancer 1986, 57: 125-128.
[19]	Smyth PPA, Smith D, Mcdermott E, Murray M, Geraghty J, O’Higgins N: A direct relationship between thyroid enlargement and breast cancer. J Clin Endocrinol Metab 1996, 81: 937-941.
[20]	Goldman ME: Thyroid diseases and breast cancer. Epidemiol Rev 1990; 16-28.
[21]	Smyth PPa: The thyroid and breast cancer: a significant association? (Editorial). Ann Med 1997; 29: 189-191.
[22]	Vanderpump Mp J, Tunbridge WMG: the epidemiology of autoimmune thyroid disease. In Contemporary Endocrinology Autoimmune Endocrinopathies. Edited by Volpe r. Totowa NJ; Humana Press; 1999: 141-162.
[23]	Taurog A: Hormone synthesis: thyroid iodine metabolism. In Werner and Ing ber’s the thyroid. Edited by Braverman L, Utiger RD. Philadelphia: Lippincott Co; 1996 47-81.
[24]	Shah NM, Eskin BA, Krouse TB, Sparks CE: Iodoprotein formation by rat mammary glands during pregnancy and early post partum period. Proc soc Exp Biol Med 1986, 181: 443-449.
[25]	Denef JF, Many MC, Van den Hove MF: Iodine induced thyroid inhibition and cell necrosis: two consequences of the same free – radical mediated mechanis? Mol Cell Endocrinol 1996, 121: 101-103.
[26]	Venturi S: Is there a role for iodine in breast diseases? The Breast 2001, 10: 379-382.
[27]	Cann SA, Van Netten JP, Van Netten C: Hypothesis: Iodine, selenium and the development of breast cancer. Cancer causes control 2000, 11; 121-127.
[28]	Kilbane MT, Ajjan RA, Weetman AP, Dwyer R, Mc Dermott EVM, O’Higgins NJ, Smyth PPA: Tissue iodine content and serum mediated I125 uptake blocking activity in breast cancer. J Clin Endocrinol Metab 2000, 85: 1245-1250.
[29]	Yoshinori Nio, Chikage iguchi, Masayuki itakura, Tomoko Toga, Koji Hasimoto et. al.,: High incidence of synchronous or metachronous breast cancer in patients with malignant and benign thyroid tumor or tumor – like disorders. Anticancer Research 2009, 29: 1607-1610.
[30]	Elsheikh SE, Green AR, Rakha EA, Powe DG, Ahmed RA et.al., (2009) Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res 69(9): 3802-9.
[31]	Diaz – Cruz ES, Furth PA (2010) Deregulated estrogen receptor α and p53 heterozygosity collaborate in the development of mammary hyperplasia: Cancer Res 62: 61-76.
[32]	Narayanan CH, Narayanan Y, Browne RC (1986) Development of the spinal tract of the trigeminal nerve and its relation to early foetal behavior in rats under normal and hypothyroid conditions. Exp Brain Res 62: 61-76.
[33]	Mihara S, Suzuki N, Wakisaka S, Suzuki N, Wakisaka S, et.al., (1999) Effects of thyroid hormones on apoptotic cell death of human lymphocytes. J Clin Endocrinol Metab 84: 1378-1385.
[34]	Hara M, Suzuki S, Mori J, Yamashita K, Kumagai M et.al.,(2000). Thyroid hormone regulation of apoptosis induced by retinoic acid in promyeloleukemic HL – 60 cells studies with retinoic acid receptor specific and retinoid X – receptor specific ligands. Thyroid 10: 1023-1024.
[35]	Utiger RD: Estrogen, thyroxine binding in serum and thyroxine therapy. N Eng J Med 2001, 344: 1784.
[36]	Hall LC, Salazar Ep, Kane SR, Liu N: Effects of thyroid hormones on human breast cancer cell proliferation. J steroid Biochem Mol Biol 2008, 109: 57-66.
[37]	Shering SG, Zbar AP, Moriarty M, Mc Dermott EW, O’Higgins NJ and smyth PP: Thyroid disorders and breast cancer. Eur J Cancer Prev 5: 504-506, 1996.
[38]	Smyth PP: the thyroid, iodine and breast cancer. Breast cancer Res 2003, 5: 235-238.
[39]	Oh HJ, Chung JK, Kang JH, Kang WJ, Noh DY, Park IA, et. al.,: The relationship between expression of the sodium / iodide symporter gene and the status of hormonal receptors in human breast cancer tissue: Cancer Res Treat, 2005, Aug; 37(4); 247-50. Epub 2005 Aug 31.
[40]	Giani C, Fierabracci P, Bonacci R, Gigliotti A, Campani D, De Negri F, et.al.,: Relationship between breast cancer and thyroid disease; relevance of autoimmune thyroid disorders in breast malignancy: J Clin Endocrinol Metab. 1996 Mar, 81(3): 990-4.
[41]	Dalla Valle L, Ramina A, Vianello S, Fassina A, Belverdere P and Colombo L: Potential for estrogen synthesis and action in human normal and neoplastic thyroid tissues. J Clin Endocrinol Metab 83: 3702-3709, 1998.
[42]	Sabitha, Suneetha, Shruthi Mohanty, Pragna Rao. Serum anti-TPO levels in benign and malignant breast tumors. Indian Journal of Clinical Biochemistry 2009 / 24 (3) 266-268.
[43]	Kandi S, Rao P. Anti-thyroid peroxidase antibodies: Its effect on thyroid gland and breast tissue. Ann Trop Med Public Health 2012; 5: 1-2.